Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 1
1967 1
1977 1
1983 2
1984 1
1985 1
1986 1
1987 2
1989 1
1991 1
1992 2
1993 3
1994 2
1995 1
1996 5
1998 2
2000 7
2001 1
2002 4
2003 1
2004 2
2005 6
2006 11
2007 8
2008 16
2009 4
2010 12
2011 13
2012 8
2013 10
2014 15
2015 10
2016 9
2017 10
2018 15
2019 9
2020 9
2021 10
2022 6
2023 9

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D'Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M, Boccadoro M. Gay F, et al. Among authors: ledda a. Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. Lancet Oncol. 2021. PMID: 34774221 Free article. Clinical Trial.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, Morè S, Corradini P, Ledda A, Gentile M, De Sabbata G, Pietrantuono G, Pascarella A, Tosi P, Curci P, Gilestro M, Capra A, Galieni P, Pisani F, Annibali O, Monaco F, Liberati AM, Palmieri S, Luppi M, Zambello R, Fazio F, Belotti A, Tacchetti P, Musto P, Boccadoro M, Gay F. Bertamini L, et al. Among authors: ledda a. J Clin Oncol. 2022 Sep 20;40(27):3120-3131. doi: 10.1200/JCO.21.01393. Epub 2022 Jun 6. J Clin Oncol. 2022. PMID: 35666982
Toxicity of nanoparticles.
Zoroddu MA, Medici S, Ledda A, Nurchi VM, Lachowicz JI, Peana M. Zoroddu MA, et al. Among authors: ledda a. Curr Med Chem. 2014;21(33):3837-53. doi: 10.2174/0929867321666140601162314. Curr Med Chem. 2014. PMID: 25306903 Review.
Giant cell arteritis and innovative treatments.
Costanzo G, Ledda AG, Sambugaro G. Costanzo G, et al. Among authors: ledda ag. Curr Opin Allergy Clin Immunol. 2023 Aug 1;23(4):327-333. doi: 10.1097/ACI.0000000000000923. Epub 2023 Jun 19. Curr Opin Allergy Clin Immunol. 2023. PMID: 37357797 Review.
Mononucleosis-related fatigue: supplementary management with Robuvit®.
Hu S, Belcaro G, Ledda A, Corsi M, Cotellese R, Feragalli B, Hosoi M, Dugall M, Torino-Rodriguez P, Cesarone MR. Hu S, et al. Among authors: ledda a. Minerva Pediatr. 2018 Oct;70(5):425-429. doi: 10.23736/S0026-4946.18.05213-1. Minerva Pediatr. 2018. PMID: 30302988
Familial occurrence of chronic myeloid leukemia.
Caocci G, Atzeni S, Vacca A, Orrù N, Ledda A, La Nasa G. Caocci G, et al. Among authors: ledda a. Leuk Lymphoma. 2009 May;50(5):854-6. doi: 10.1080/10428190902842634. Leuk Lymphoma. 2009. PMID: 19452324 Review. No abstract available.
Bayesian Inference of Clonal Expansions in a Dated Phylogeny.
Helekal D, Ledda A, Volz E, Wyllie D, Didelot X. Helekal D, et al. Among authors: ledda a. Syst Biol. 2022 Aug 10;71(5):1073-1087. doi: 10.1093/sysbio/syab095. Syst Biol. 2022. PMID: 34893904 Free PMC article.
221 results